Iodine-131 meta-iodobenzylguanidine (131I-MIBG) for the localization of suspected phaeochromocytoma

123I‐metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra‐adrenal phaeochromocytomas: CT and MRI correlation

“…This has resulted in superior image quality and increased sensitivity, and allows single photon emission CT (SPECT) imaging 2 . The sensitivity of [ 131 I]MIBG imaging for phaeochromocytoma detection is well established from numerous large series, varying between 79% and 94%, with a specificity of 92%, 3–15 but comparable data using [ 123 I]MIBG are currently limited to fewer and smaller series 2,16–19 . In general, the sensitivity of [ 123 I]MIBG from these series varies between 88% and 100% and the specificity approaches 100%, although a recent meta‐analysis of published series with > 5 tumours calculated a sensitivity of 98% for adrenal and extra‐adrenal phaeochromocytomas 18 .…”

The usefulness of [131I]‐metaiodobenzylguanidine ([131I]‐MIBG) scintigraphy performed one week after administration in diagnosing pheochromocytoma

“…In fact, there is a report where imaging was carried out 5 days after administration. 12 Warren et al 13 carried out imaging 7 days after administration, for the purpose of finding the change in the accumulated part or removing the accumulated part in the later stage. Lindberg et al 10 reported three cases which could not be diagnosed to be positive until 7 days after administration and emphasized the usefulness of the late imaging.…”